The present invention provides variant activin IIB soluble receptors polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides. Compositions and methods for treating muscle-wasting and metabolic and other diseases and disorders are also provided.